(Bloomberg) — Alibaba Group Holding Ltd. shares slipped as much as 6.6% in U.S. trading on Monday after Citigroup Inc. analysts saw its additional American depositary share registration in the U.S. as a sign that SoftBank Group Corp. may intend to sell part of its stake.
Most Read from Bloomberg
Ottawa Declares Emergency as Protests Spin ‘Out of Control’
Redistricting Is Taking the Swing Out of U.S. Swing States
Joe Manchin Predicts Passage for U.S. Electoral Reform Act
Adults Back in Charge of Stock Market as Fed Awakens Big Money
Amazon Prime Fee Rising to $180, Not $139, for Many Members
A potential stake sale by early investor Softbank would likely weaken sentiment toward Alibaba’s shares, battered last year along with other Chinese technology peers by Beijing’s regulatory crackdowns. The stock is down 3.2% this year and more than 63% below its October 2020 highs.
SoftBank owns 5.39 billion ordinary Alibaba shares, equivalent to 673.76 million ADSs, or a 24.8% stake, according to Citi’s calculations. Masayoshi Son’s SoftBank has faced pressure from investors in recent months as the value of many portfolio companies, including Didi Global Inc., One 97 Communications Ltd. and DoorDash Inc. was dragged lower by the technology downturn.
Alibaba filed a form on Friday with the Securities and Exchange Commission of the U.S. to register an additional one billion ADSs, each representing eight ordinary shares. The filing will allow its stockholders whose shares have never been registered with the regulator to have the flexibility to sell stock, Citi said. The registration could also cover the company’s need to issue new shares for an employee equity incentive plan.
Despite Alibaba’s rout, the Nasdaq Golden Dragon China Index was traded 0.5% on Monday after China shares overnight showed strong momentum after a week-long holiday. The gauge closed 8% higher last week, its biggest rally in about two months.
(Updated Baba move and added last paragraph with Golden Dragon Index mention)
Most Read from Bloomberg Businessweek
The Rise of the $2.5 Billion Ugly-Shoe Empire
Nurses Who Faced Lawsuits for Quitting Are Fighting Back
New Airline Bets You’ll Stop in Alaska for a Cheaper Flight to Asia
Merck’s Covid Pill Fumble Gives Pfizer Potential $17 Billion Win
The Nuclear Industry Argues Regulators Don’t Understand New Small Reactors
©2022 Bloomberg L.P.
